This is a non-core endpoint: only basic statistics are computed.
Other benign neoplasm of uterus: Cervix uteri
CD2_BENIGN_CERVIX_UTERI_EXALLC
No definition available.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
|
1. Apply sex-specific ruleonly females |
- |
2. Check conditionsNone |
|
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
- |
4. Check minimum number of eventsNone |
- |
5. Include endpointsNone |
- |
6. Filter based on genotype QC (FinnGen only)None |
- |
Control definitions (FinnGen only)
- Control exclude
- C3_CANCER, C3_CANCER_WIDE
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- D26
- Name in latin
- Neoplasma benignum cervicis uteri
Similar endpoints
↥List of similar endpoints to
Other benign neoplasm of uterus: Cervix uteri
based on the number of shared cases.
Similar with more cases:
- Other benign neoplasm of uterus: Cervix uteri
- Other benign neoplasms of uterus
- Other benign neoplasms of uterus
- Benign neoplasms
- Benign neoplasms
Similar with less cases:
Case counts by codes
↥FinnGen case counts by registry codes:
No upset plot: script not run.
No upset table: script not run.
Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 214 | 214 | - |
| Unadjusted period prevalence (%) | 0.07 | 0.07 | - |
| Median age at first event (years) | 47.37 | 47.37 | - |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 185
- Matched controls
- 1848
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
D26.0
ICD-10 Finland
Other benign neoplasm: Cervix uteri
5070.3
169.6
137
*
2190A
ICD-9 Finland
Other benign neoplasm of uterus, Cervix uteri
+∞
51.5
47
*
PJA12
NOMESCO Finland
Sentinel node biopsy
+∞
18.0
17
*
LDB00
NOMESCO Finland
Excision of lesion of cervix uteri
19.9
17.5
26
15
115
Kela drug reimbursment
Breast cancer
+∞
15.9
15
*
N84.1
ICD-10 Finland
Polyp of cervix uteri
8.6
11.6
25
33
HA003
NOMESCO Finland
Radiotherapy after partial ablation of mammary gland
+∞
11.6
11
*
8113
FHL
Fractional scraping
5.3
11.5
36
80
H02AB02
ATC
dexamethasone; systemic
14.5
9.9
16
12
L02BA01
ATC
tamoxifen; oral
105.2
9.5
10
*
WB113
NOMESCO Finland
Multiple adjuvant cytostatic therapy
+∞
9.5
9
*
HAC20
NOMESCO Finland
Total mastectomy
52.5
8.8
10
*
ZX012
NOMESCO Finland
Radiotherapy with large shaped fields - isocentric therapy
94.2
8.5
9
*
C50.41
ICD-10 Finland
Malignant tumor of the upper outer quadrant of the mammary gland, ductal tumor
+∞
8.4
8
*
C50.42
ICD-10 Finland
Malignant tumor of the upper outer quadrant of the mammary gland, lobular tumor
+∞
7.3
7
*
WF003
NOMESCO Finland
Adjuvant radiotherapy
+∞
7.3
7
*
A04AA02
ATC
granisetron; systemic, transdermal
+∞
7.3
7
*
JN4BD
NOMESCO Finland
Extensive body CT
7.7
6.9
15
21
PJ5AN
NOMESCO Finland
Localisation of sentinell lymphnode with isotope imaging
+∞
6.3
6
*
YG1BD
NOMESCO Finland
Extensive CT examination of thorax for dose design of radiotherapy
+∞
6.3
6
*
A04AA55
ATC
palonosetron, combinations; systemic
+∞
6.3
6
*
8500/3-C50.9
ICD-O-3
Infiltrating duct carcinoma, NOS, of breast, NOS
+∞
6.3
6
*
A04AA01
ATC
ondansetron; systemic, rectal
8.1
6.2
13
17
LC2BE
NOMESCO Finland
Transvaginal ultrasound examination of uterus, parametria and lower abdomen
2.2
6.1
83
499
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
25
82
3.32
6.43
2.1
1.6
5.1
2.7
ug/l
0.39
19
61
12
23
5.47
6.08
1.3
1.2
—
—
—
0
0
23
96
2.56
3.88
1.4
1.5
—
—
—
0
0
161
1325
1.87
3.80
7.4
5.2
80.6
74.1
u/l
0.50
150
1213
24
104
2.47
3.75
1.5
1.6
—
—
—
0
0
111
834
1.69
3.49
5.4
3.2
9.3
10.1
umol/l
0.51
106
774
26
131
2.12
2.90
1.9
1.7
—
—
—
0
0
80
575
1.62
2.85
3.7
2.0
2.4
2.4
mmol/l
0.49
68
480
5
8
6.37
2.38
1.8
1.6
—
—
—
0
0
12
47
2.65
2.31
1.5
1.3
—
—
—
0
0
68
492
1.56
2.28
1.4
1.4
—
—
—
0
0
23
124
1.96
2.17
2.7
3.6
282.3
246.5
u/l
0.29
23
116
5
10
5.09
2.08
1.2
1.4
—
—
—
0
0
117
963
1.47
2.08
8.0
6.5
3.8
4.1
e9/l
0.73
103
841
6
16
3.83
1.95
1.2
1.3
—
—
—
0
0
5
12
4.24
1.83
1.2
1.3
—
—
—
0
0
37
246
1.61
1.76
2.6
2.7
5.1
4.5
e6/l
0.09
20
124
50
358
1.52
1.73
1.8
1.7
512195564.6
41414603.8
pmol/l
0.64
41
297
70
542
1.43
1.63
2.4
2.0
52.9
55.2
u/l
0.40
65
496
90
732
1.40
1.58
4.9
4.0
1.2
1.2
mmol/l
0.11
77
656
55
409
1.46
1.58
1.7
1.7
1.0
0.8
mg/l
0.21
43
312
112
951
1.37
1.49
4.2
3.4
6.5
6.4
mmol/l
0.06
101
873
98
818
1.37
1.44
6.4
4.4
1.2
1.2
mmol/l
1.01
83
704
23
145
1.66
1.36
2.0
1.8
—
—
—
0
0
12
61
2.02
1.35
1.5
1.3
155.4
56.3
pmol/l
0.46
12
61
23
146
1.64
1.32
2.0
1.8
—
—
—
0
0
20
124
1.68
1.26
1.2
1.3
28.1
28.5
iu/l
0.02
20
110
31
215
1.52
1.25
2.0
1.8
—
—
—
0
0
170
1566
1.42
1.24
4.8
4.3
14.7
14.6
pmol/l
0.27
158
1453
6
26
2.34
1.19
2.8
1.3
—
—
—
0
0
10
50
2.05
1.18
1.3
1.1
—
—
—
0
0
20
127
1.63
1.16
3.1
3.0
1.1
2.4
mmol/l
1.30
13
102
134
1201
1.31
1.10
3.4
2.7
45.9
37.2
u/l
0.56
123
1124
14
82
1.76
1.08
1.7
1.5
—
—
—
0
0
106
924
1.29
1.06
4.2
3.6
0.2
0.0
estimate
0.48
19
154
105
915
1.29
1.05
4.2
3.6
0.0
0.0
estimate
0.00
17
158
68
559
1.32
1.05
2.9
2.8
—
—
—
0
0
105
916
1.29
1.04
6.5
5.0
0.0
0.0
estimate
0.00
17
155
5
22
2.30
1.04
1.2
1.3
—
—
—
0
0
12
68
1.81
1.03
1.3
1.5
288.8
289.6
mu/l
0.00
12
62
179
1683
1.39
0.98
16.4
12.0
38.4
39.7
%
0.92
127
1246
21
142
1.53
0.96
5.4
5.1
1.6
1.7
mmol/l
0.05
16
115
6
27
2.26
0.94
1.3
1.3
—
—
—
0
0
6
28
2.17
0.92
1.5
1.0
—
—
—
0
0
113
1251
0.80
0.90
4.1
3.3
—
—
—
0
0
8
42
1.94
0.89
1.1
1.5
—
—
—
0
0
193
1846
1.46
0.88
4.8
4.3
5.8
5.8
mmol/l
0.17
180
1700
6
30
2.03
0.87
1.3
1.3
—
—
—
0
0
16
104
1.58
0.87
1.9
1.6
—
—
—
0
0
12
72
1.71
0.87
3.3
2.7
24.5
25.6
mmol/l
0.82
12
72
30
225
1.39
0.84
1.4
1.9
—
—
—
0
0
11
66
1.70
0.80
4.2
2.7
52.5
45.1
%
0.35
11
66
0
25
0.00
0.79
0.0
1.1
—
—
—
0
0
196
1886
1.47
0.79
15.0
11.8
139.7
139.8
mmol/l
0.34
189
1834
39
310
1.32
0.76
1.6
1.6
1286.2
1207.8
nmol/l
0.18
30
229
9
55
1.66
0.74
1.4
1.6
—
—
—
0
0
181
1725
1.32
0.73
6.3
5.3
39.1
38.9
mmol/mol
0.11
167
1616
34
272
1.30
0.65
2.6
2.4
1.9
1.1
e6/l
0.39
18
150
98
883
1.20
0.65
3.3
2.9
85.2
71.6
ug/l
0.68
92
821
12
79
1.55
0.64
2.0
2.8
0.2
0.2
e6/l
0.10
12
73
26
202
1.33
0.61
1.5
1.8
—
—
—
0
0
8
52
1.56
0.60
2.0
1.7
—
—
—
0
0
50
424
1.23
0.60
3.0
2.2
2.8
3.0
mg/l
0.27
42
357
195
1890
1.36
0.58
15.1
11.8
4.0
3.9
mmol/l
0.62
188
1833
23
178
1.33
0.56
3.7
2.3
20.0
22.7
%
0.46
18
151
47
404
1.21
0.50
2.2
1.5
—
—
—
0
0
10
68
1.49
0.48
1.3
1.8
—
—
—
0
0
201
1965
1.38
0.47
11.1
8.6
24.1
23.2
u/l
0.45
192
1889
5
31
1.63
0.43
1.2
1.4
—
—
—
0
0
5
31
1.63
0.43
1.2
1.4
—
—
—
0
0
5
32
1.58
0.42
1.2
1.9
—
—
—
0
0
5
32
1.58
0.42
2.4
2.3
—
—
—
0
0
27
223
1.24
0.42
4.9
4.7
—
—
—
0
0
0
15
0.00
0.41
0.0
1.0
—
—
—
0
0
0
15
0.00
0.41
0.0
1.1
—
—
—
0
0
0
15
0.00
0.41
0.0
1.1
—
—
—
0
0
0
16
0.00
0.41
0.0
1.1
—
1.1
—
0
9
14
182
0.75
0.41
1.0
1.2
244.2
131.4
iu/ml
—
7
80
8
60
1.35
0.40
1.9
1.9
—
—
—
0
0
36
417
0.84
0.40
1.7
1.5
21.5
22.7
nmol/l
0.20
30
360
7
101
0.68
0.40
2.0
1.5
—
—
—
0
0
79
723
1.15
0.40
4.3
3.7
—
—
—
0
0
10
71
1.43
0.40
1.9
2.1
1.1
1.1
%
—
10
71
0
19
0.00
0.39
0.0
1.3
—
—
—
0
0
9
70
1.30
0.37
7.0
5.2
1.6
1.4
%
—
9
70
9
123
0.72
0.36
1.9
1.3
—
—
—
0
0
180
1750
1.18
0.35
10.4
9.4
82.0
82.4
ml/min/173m2
0.09
136
1391
6
44
1.37
0.34
2.2
1.2
—
—
—
0
0
6
45
1.34
0.34
1.5
1.5
—
—
—
0
0
19
156
1.24
0.32
4.6
3.7
106.3
103.5
mmol/l
2.03
19
151
195
1912
1.22
0.31
4.7
4.8
2.9
2.9
mmol/l
0.06
180
1775
26
222
1.19
0.31
4.7
4.4
34.2
33.8
%
0.06
15
136
36
317
1.16
0.31
3.6
3.9
239.6
116.7
ng/l
0.28
23
227
66
608
1.12
0.30
2.9
3.3
197.7
27.6
ng/l
0.47
37
376
9
72
1.26
0.26
2.4
1.8
—
—
—
0
0
39
351
1.14
0.25
1.9
1.9
—
—
—
0
0
51
470
1.11
0.23
1.3
1.3
0.5
2.3
u/ml
1.18
17
136
83
785
1.09
0.23
4.7
3.5
—
—
—
0
0
47
432
1.11
0.22
3.1
2.7
0.4
0.4
e6/l
0.01
29
317
44
403
1.12
0.22
1.4
1.3
1.0
8.6
u/ml
2.39
19
151
5
42
1.19
0.21
1.2
1.6
—
—
—
0
0
0
11
0.00
0.21
0.0
1.5
—
—
—
0
0
0
10
0.00
0.21
0.0
1.1
—
1725.2
—
0
10
0
12
0.00
0.21
0.0
1.9
—
—
—
0
0
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
57
533
1.09
0.20
2.3
2.0
108.5
128.2
u/l
0.54
49
503
5
69
0.72
0.17
1.6
1.2
—
—
—
0
0
5
69
0.72
0.17
1.0
2.7
29.4
42.3
u/l
—
5
63
5
70
0.71
0.17
1.6
1.2
—
—
—
0
0
187
1843
1.12
0.16
15.6
10.6
20.2
18.5
mg/l
0.35
147
1391
17
149
1.15
0.16
2.1
2.9
—
—
—
0
0
46
433
1.08
0.14
2.3
2.7
620.4
890.6
ng/l
0.84
39
360
9
109
0.82
0.13
1.2
1.4
—
—
—
0
0
76
734
1.05
0.11
1.9
1.9
112.9
100.2
pmol/l
1.01
38
354
50
480
1.05
0.09
3.5
3.9
0.0
0.0
estimate
0.00
19
158
6
56
1.07
0.08
1.5
1.8
—
—
—
0
0
7
68
1.03
0.08
7.9
3.3
24.5
25.4
mmol/l
—
7
68
86
840
1.04
0.07
2.3
2.3
79.9
79.6
nmol/l
0.03
80
750
183
1815
1.06
0.06
5.8
5.0
1.9
2.5
mu/l
0.41
169
1680
144
1423
1.04
0.06
4.8
4.3
12.2
11.2
mm/h
0.51
132
1314
53
545
0.96
0.05
1.6
1.6
1.5
1.4
mmol/l
0.51
48
463
180
1789
1.04
0.03
3.8
3.9
1.2
1.2
mmol/l
0.11
166
1650
12
112
1.08
0.03
1.0
1.1
—
—
—
0
0
188
1872
1.04
0.02
4.3
4.3
1.6
1.6
mmol/l
0.14
178
1740
189
1886
1.02
0.00
4.4
4.3
4.8
4.9
mmol/l
0.20
180
1759
41
409
1.00
0.00
1.3
1.3
16.1
40.4
iu/ml
2.35
12
139
13
133
0.98
0.00
2.8
2.9
117.5
185.4
ng/l
0.67
13
122
19
185
1.03
0.00
1.5
1.7
—
—
—
0
0
0
5
0.00
0.00
0.0
1.6
—
57.7
—
0
5
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
341.6
—
0
5
0
5
0.00
0.00
0.0
3.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
0
9
0.00
0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
9
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.4
—
—
—
0
0
0
6
0.00
0.00
0.0
1.7
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
0.00
0.0
4.2
—
543.0
—
0
9
0
6
0.00
0.00
0.0
1.5
—
—
—
0
0
0
6
0.00
0.00
0.0
1.7
—
—
—
0
0
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
0
8
0.00
0.00
0.0
1.8
—
—
—
0
0
0
6
0.00
0.00
0.0
1.7
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.5
—
—
—
0
0
0
9
0.00
0.00
0.0
1.3
—
—
—
0
0
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
0
8
0.00
0.00
0.0
1.8
—
—
—
0
0
0
9
0.00
0.00
0.0
1.2
—
—
—
0
0
0
9
0.00
0.00
0.0
1.6
—
—
—
0
0
5
58
0.86
0.00
2.0
1.5
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: CD2_BENIGN_CERVIX_UTERI_EXALLC – Other benign neoplasm of uterus: Cervix uteri
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).